{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-21-001925","form_type":"8-K","ticker":"CRBU","cik":"0001619856","company_name":"Caribou Biosciences, Inc.","filed_at":"2021-09-29T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.896532+00:00","generated_at":"2026-06-29T00:42:53.221065+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Caribou Biosciences appoints Ran Zheng to board of directors","bullets":["Board increased from 5 to 6 directors; Zheng appointed Class I director and to Nominating Committee.","Zheng receives $40,000/yr board cash compensation plus $4,000/yr committee cash compensation.","Initial grant of 44,000 non-qualified stock options, vesting over 3 years starting Oct 1, 2022.","Zheng brings 25+ years biotech experience, most recently CEO of Landmark Bio and CTO at Orchard Therapeutics.","Press release issued Sep 29, 2021; option exercise price = closing price on Oct 1, 2021 grant date."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-21-001925","json":"https://secwatch.observer/filing/0000950170-21-001925.json","markdown":"https://secwatch.observer/filing/0000950170-21-001925.md","text":"https://secwatch.observer/filing/0000950170-21-001925.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1619856/000095017021001925/0000950170-21-001925-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1619856/000095017021001925/crbu-20210924.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T00:42:53.221065+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fcf4d919c2","claim":"Ran Zheng was appointed as Class I Director at Caribou Biosciences, Inc..","evidence_excerpt":"On September 24, 2021, the Board of Directors (the “Board”) of Caribou Biosciences, Inc., a Delaware corporation (the “Company”), increased the size of the Board from five to six directors and unanimously agreed to extend an offer to Ran Zheng to serve as a Class I director of the Company, which offer Ms. Zheng accepted on September 24, 2021.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1619856/000095017021001925/0000950170-21-001925-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class I Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}